Nuva Ring and Dangerous Products

People living in the United States have access to highly evolved forms of medicine. Before 1960, women didn’t have access to birth control pills but now, there are numerous forms of hormonal contraceptives. In addition to oral contraceptives, birth control is available in the form of a patch, an implant, a vaginal ring, a shot, and an intrauterine device. With the guidance of their doctors, women make informed decisions about which birth control form suits them best based on their lifestyle, predisposed medical conditions, and personal preferences.

Women enjoy access to these pharmaceutical innovations as pharmaceutical companies enjoy the financial benefits of catering to a high-demand market. Unfortunately, as hormonal birth control advances at a quick rate, women often take a birth control remedy that isn’t proven completely safe yet. As pharmaceutical contraceptives prove to be advantageous, they also prove to be dangerous products. Women are at a higher risk than men of experiencing complications from blood clots. Whenever women take birth control, this risk increases. Hormonal birth control multiplies this pre-existing risk unnecessarily in some women.

Women who are aware of pre-existing blood-pressure problems typically opt to take progestin-only birth control pills, as combination progestin-oestrogen pills cause the most circulatory issues. However, many women who suffer from blood clot complications due to their hormonal birth control do not display any pre-existing risk for developing blood clots.

The NuvaRing is appealing to many women as a contraceptive because it is convenient. The NuvaRing is inserted into the vagina and remains for 21 days. After 21 days, it is removed for 7 days. Women who can’t remember to take a pill daily find this option very user-friendly. However convenient women find this form of birth control, according to the website of the attorneys at Williams Kherkher, the hormonal birth control method NuvaRing has caused complications like blood clotting, deep vein thrombosis, pulmonary embolism, and stoke. More than 1,000 lawsuits against NuvaRing may go to trial the fall of 2013.